Cancer Diagnostic Firm Theralink To Merge With IMAC Holdings
Portfolio Pulse from Vandana Singh
Cancer diagnostic firm Theralink Technologies is set to merge with IMAC Holdings (NASDAQ:BACK) in a stock-for-stock reverse merger transaction. The combined company will focus on end-to-end proteomics testing. The merger is expected to close by late Q3 or early Q4 of 2023.
May 23, 2023 | 6:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IMAC Holdings (NASDAQ:BACK) is merging with Theralink Technologies in a stock-for-stock reverse merger transaction, with the combined company focusing on end-to-end proteomics testing.
The merger between Theralink Technologies and IMAC Holdings will result in a combined company focusing on end-to-end proteomics testing. This could potentially lead to growth and expansion in the healthcare sector. As a result, IMAC Holdings' stock price is likely to be positively impacted in the short term, as evidenced by the 12.80% increase in share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100